Skip to main content
. 2024 Nov 14;26:158. doi: 10.1186/s13058-024-01907-5

Table 2.

The association between body mass index and breast cancer risk in Asian women by menopausal status at baseline

Body mass index at baseline (kg/m2)
 < 18.5 18.5– < 21 21– < 23 23– < 25 25– < 27.5 27.5– < 30 30- Trend (per 5 kg/m2)
HR (95% CI) HR (95% CI) HR HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) p
Premenopausal women
Number of participants 5,862 27,243 32,295 26,556 17,294 6,566 2,970
Person-years 115,078 509,956 589,871 483,623 315,679 119,619 53,686
Number of cases 92 470 578 496 370 135 61
Crude rate (per 100,000) 79.95 92.16 97.99 102.56 117.21 112.86 113.62
Age- and study-adjusted (HR1) 0.86 (0.69–1.07) 0.97 (0.86–1.10) 1 (ref.) 1.01 (0.89–1.14) 1.12 (0.99–1.28) 1.07 (0.89–1.29) 1.11 (0.85–1.44) 1.08 (1.01–1.16) 0.02
Multivariate-adjusted (HR2)a 0.86 (0.69–1.07) 0.97 (0.86–1.10) 1 (ref.) 1.01 (0.90–1.14) 1.13 (0.99–1.28) 1.07 (0.89–1.29) 1.11 (0.85–1.44) 1.08 (1.01–1.16) 0.02
Multivariate-adjusted (HR3)b 0.83 (0.67–1.04) 0.96 (0.85–1.08) 1 (ref.) 1.01 (0.90–1.14) 1.13 (0.99–1.29) 1.08 (0.89–1.30) 1.11 (0.85–1.44) 1.09 (1.02–1.17) 0.01
(Excluding cases within 3 years)
Multivariate-adjusted (HR2)a 0.85 (0.66–1.08) 0.93 (0.81–1.07) 1 (ref.) 1.01 (0.89–1.16) 1.13 (0.98–1.30) 1.13 (0.93–1.38) 1.03 (0.77–1.39) 1.10 (1.02–1.18) 0.01
Multivariate-adjusted (HR3)b 0.82 (0.64–1.05) 0.92 (0.80–1.05) 1 (ref.) 1.01 (0.89–1.16) 1.14 (0.99–1.31) 1.15 (0.94–1.40) 1.03 (0.77–1.39) 1.11 (1.03–1.20) 0.005
Postmenopausal women
Number of participants 11,885 34,326 46,852 45,963 37,651 16,091 7,635
Person-years 167,878 526,765 734,224 727,835 595,491 254,248 117,526
Number of cases 98 331 526 669 564 276 153
Crude rate (per 100,000) 58.38 62.84 71.64 91.92 94.71 108.56 130.18
Age- and study-adjusted (HR1) 0.83 (0.67–1.03) 0.89 (0.77–1.02) 1 (ref.) 1.26 (1.12–1.41) 1.27 (1.13–1.43) 1.40 (1.21–1.62) 1.64 (1.37–1.96) 1.28 (1.21–1.35)  < 0.001
Multivariate-adjusted (HR2)a 0.83 (0.67–1.03) 0.89 (0.77–1.02) 1 (ref.) 1.26 (1.12–1.41) 1.27 (1.13–1.44) 1.40 (1.21–1.62) 1.64 (1.37–1.97) 1.28 (1.22–1.35)  < 0.001
Multivariate-adjusted (HR4)c 0.80 (0.64–1.00) 0.87 (0.76–1.00) 1 (ref.) 1.27 (1.13–1.42) 1.30 (1.15–1.46) 1.43 (1.24–1.66) 1.72 (1.43–2.06) 1.32 (1.25–1.39)  < 0.001
(Excluding cases within 3 years)
Multivariate-adjusted (HR2)a 0.80 (0.63–1.02) 0.87 (0.75–1.02) 1 (ref.) 1.22 (1.08–1.39) 1.28 (1.12–1.46) 1.46 (1.24–1.71) 1.72 (1.42–2.10) 1.31 (1.24–1.39)  < 0.001
Multivariate-adjusted (HR4)c 0.77 (0.60–0.99) 0.85 (0.73–1.00) 1 (ref.) 1.23 (1.08–1.40) 1.31 (1.14–1.49) 1.50 (1.28–1.75) 1.80 (1.48–2.19) 1.35 (1.27–1.43)  < 0.001

HR hazard ratio, CI confident interval, ref reference

aEstimated hazard ratio after adjustments for age at enrollment (continuous), study (13 cohorts), smoking status (never, former, current smokers), and alcohol consumption (non-drinkers or current drinkers)

bEstimated hazard ratio after adjustments for age at enrollment (continuous), study (13 cohorts), smoking status (never, former, current smokers), alcohol consumption (non-drinkers or current drinkers), age at menarche (≤ 10 y, 11–12 y, 13–14 y, 15–16 y, ≥ 17 y), nulliparity (yes, no), and age at first delivery (≤ 20 y, 21–25 y, 26–30 y, ≥ 31 y)

cEstimated hazard ratio after adjustments for age at enrollment (continuous), study (13 cohorts), smoking status (never, former, current smokers), alcohol consumption (non-drinkers or current drinkers), age at menarche (≤ 10 y, 11–12 y, 13–14 y, 15–16 y, ≥ 17 y), nulliparity (yes, no), age at first delivery (≤ 20 y, 21–25 y, 26–30 y, ≥ 31 y), and age at menopause (≤ 44 y, 45–49 y, 50–54 y, ≥ 55 y)